|
1.
|
Lopes C, Dina C, Durand E and Froguel P:
PAI-1 polymorphisms modulate phenotypes associated with the
metabolic syndrome in obese and diabetic Caucasian population.
Diabetologia. 46:1284–1290. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Zhang ZY, Wang ZY, Dong NZ, Bai X, Zhang W
and Ruan CG: A case of deficiency of plasma plasminogen activator
inhibitor-1 related to Ala15Thr mutation in its signal peptide.
Blood Coagul Fibrinolysis. 16:79–84. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Fay WP, Parker AC, Condrey LR and Shapiro
AD: Human plasminogen activator inhibitor-1 (PAI-1) deficiency:
characterization of a large kindred with a null mutation in the
PAI-1 gene. Blood. 90:204–208. 1997.PubMed/NCBI
|
|
4.
|
Evans PA, Hawkins K, Lawrence M, Barrow
MS, Williams PR and Williams RL: Studies of whole blood coagulation
by oscillatory shear, thromboelastography and free oscillation
rheometry. Clin Hemorheol Microcirc. 38:267–277. 2008.PubMed/NCBI
|
|
5.
|
Gallimore MJ, Harris SL, Tappenden KA,
Winter M and Jones DW: Urokinase induced fibrinolysis in
thromboelastography: a model for studying fibrinolysis and
coagulation in whole blood. J Thromb Haemost. 3:2506–2513. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Carr ME Jr, Krishnamurti C and Alving BM:
Effect of plasminogen activator inhibitor-1 on tissue-type
plasminogen activator-induced fibrinolysis. Thromb Haemost.
67:106–110. 1992.PubMed/NCBI
|
|
7.
|
Sugiki M, Maruyama M, Yoshida E, Mihara H,
Kamiguti AS and Theakston DG: Enhancement of plasma fibrinolysis in
vitro by jararhagin, the main haemorrhagic metalloproteinase in
Bothrops jararaca venom. Toxicon. 33:1605–1617. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Jankun J, Aleem AM, Selman SH, et al:
Highly stable plasminogen activator inhibitor type one (VLHL PAI-1)
protects fibrin clots from tissue plasminogen activator-mediated
fibrinolysis. Int J Mol Med. 20:683–687. 2007.
|
|
9.
|
Kohro S, Yamakage M, Omote T and Namiki A:
In vitro effects of propofol on blood coagulability and
fibrinolysis by the use of thromboelastograph technique. Acta
Anaesthesiol Scand. 43:217–219. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Agren A, Wiman B and Schulman S:
Laboratory evidence of hyperfibrinolysis in association with low
plasminogen activator inhibitor type 1 activity. Blood Coagul
Fibrinolysis. 18:657–660. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Perkowska A, Elhasade A, Durlik M, et al:
The effect of chronic allograft rejection on plasma regulators of
fibrinolysis. Ann Transplant. 7:44–51. 2002.PubMed/NCBI
|
|
12.
|
TEG 5000 User's Manual Version 4.2
Software. Haemoscope Corporation 2006.
|
|
13.
|
Jankun J, Aleem AM, Struniawski R,
Lysiak-Szydlowska W, Selman SH and Skrzypczak-Jankun E: Accelerated
thrombus lysis in the blood of plasminogen activator inhibitor
deficient mice is inhibited by PAI-1 with a very long half-life.
Pharmacol Rep. 61:673–680. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Mehta R and Shapiro AD: Plasminogen
activator inhibitor type 1 deficiency. Haemophilia. 14:1255–1260.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Schleef RR, Higgins DL, Pillemer E and
Levitt LJ: Bleeding diathesis due to decreased functional activity
of type 1 plasminogen activator inhibitor. J Clin Invest.
83:1747–1752. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Jankun J and Skrzypczak-Jankun E: Yin and
yang of the plasminogen activator inhibitor. Pol Arch Med Wewn.
119:410–417. 2009.PubMed/NCBI
|
|
17.
|
Repine T and Osswald M: Menorrhagia due to
a qualitative deficiency of plasminogen activator inhibitor-1: case
report and literature review. Clin Appl Thromb Hemost. 10:293–296.
2004. View Article : Google Scholar : PubMed/NCBI
|
